Nyxoah Reports Soaring Revenue, Positive Guidance Amidst U.S. Launch Success; Institutional Investor Reduces Stake

summarizeSummary

Nyxoah reported robust Q4 and full-year 2025 revenue growth, driven by strong U.S. commercialization post-FDA approval, and provided positive sequential revenue guidance, despite widening losses and a significant institutional share sale.

check_boxKey Events

• Strong Q4 and Full Year 2025 Revenue Growth

  Fourth quarter net revenue surged 347% year-over-year to €5.6 million, with full-year net revenue growing 122% to €10.0 million, primarily driven by the first full quarter of U.S. commercialization.

• Positive U.S. Commercialization Momentum

  Following FDA approval in August 2025, the company trained 145 surgeons and activated 57 accounts in the U.S., with the Genio system consistently reimbursed by commercial payors and Medicare.

• Optimistic Revenue Guidance

  Nyxoah expects U.S. net revenue to grow approximately 25% sequentially in both the first and second quarters of 2026.

• Significant Institutional Share Sale

  BNP Paribas Asset Management reported crossing below the 3% ownership threshold, indicating a disposition of approximately $4.14 million worth of shares, representing 3.07% of the company's market capitalization.

auto_awesomeAnalysis

This 6-K filing, while furnishing previously announced earnings via GlobeNewswire, also includes new transparency notifications. The core positive takeaway is the company's strong operational performance, with Q4 net revenue surging 347% year-over-year and full-year revenue growing 122%, primarily due to the successful U.S. commercial launch of its Genio system. The positive sequential U.S. revenue guidance for Q1 and Q2 2026 further reinforces this momentum, suggesting continued growth. This strong operational news is particularly impactful given the stock is trading near its 52-week lows, potentially signaling a turning point. However, the filing also reveals a significant share disposition by BNP Paribas Asset Management, representing over 3% of the company's market cap, which introduces a negative sentiment from an institutional investor's perspective. While widening operating losses are noted, they are attributed to strategic investments in commercialization and R&D, which is typical for a growth-stage medical technology company. Investors should weigh the strong commercial execution and future growth prospects against the institutional selling pressure.